A disciplined, highly targeted approach to discovering new cancer medicines
Rigorous, definitive clinical trials based on deep oncology expertise
Committed to bringing differentiated new cancer medicines to patients
ARIAD's first internally discovered and developed medicine
ARIAD Announces Full Enrollment in Phase 2 ALTA Trial of Brigatinib
ARIAD Announces First Patient Treated in Phase 2 Dose-Ranging Optic Trial of Iclusig (Ponatinib)
A shared commitment to patients and each other. This is ARIAD.